Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Clotalyst is a chitosan-based hemostatic agent designed to rapidly control moderate to severe bleeding. Developed by HemCon Medical Technologies, it utilizes the mucoadhesive properties of chitosan, a naturally occurring polysaccharide derived from crustacean shells. When applied to a wound, the positively charged chitosan molecules attract and bind with negatively charged red blood cells, leading to rapid erythrocyte aggregation and the formation of a physical plug that seals the injury site. This mechanism of action is independent of the body's physiological coagulation cascade, making it effective even in patients with coagulopathies or those on anticoagulant therapy. It is primarily indicated for external temporary control of severely bleeding wounds in trauma and surgical settings.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Clotalyst.